The new division, known as Lonza custom manufacturing, consolidates the Swiss firm’s suite of R&D and production services for chemicals, intermediates, active pharmaceutical ingredients (API) and biotherapeutics.
Lonza will hope that the new group’s broad offering will be able to win contract manufacturing business from a diverse range of pharmaceutical players, particularly those seeking biomanufacturing and development solutions.
Stephen Kutzer and Uwe Boehlke, from Lonza’s biopharmaceutical and exclusive synthesis groups, will jointly lead the new unit.
